Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
Crossref DOI link: https://doi.org/10.1007/s10147-018-1241-3
Published Online: 2018-01-11
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ishihara, Hiroki http://orcid.org/0000-0002-5146-656X
Takagi, Toshio
Kondo, Tsunenori
Tachibana, Hidekazu
Yoshida, Kazuhiko
Omae, Kenji
Iizuka, Junpei
Kobayashi, Hirohito
Tanabe, Kazunari
License valid from 2018-01-11